{"id":"80e6fa9e-9aa3-51fa-89ac-6e765d9eb7fd","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-hpv-null","predicate":"did_not_reduce_trial","statement":"Among baseline HPV-positive women, 69% on DIM versus 61% on placebo remained positive at six months, RR 1.1 with 95% CI 0.9-1.4.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"7a926a97-b287-5f42-b163-3267b258a30d","mechanism_event_label":"This trial did not demonstrate improved HPV clearance.","subject":{"id":"6009bdd4-f1b5-5867-b5c3-cdf7c9645cd0","slug":"dim","display_name":"3,3'-Diindolylmethane / DIM","entity_type_key":"small_molecule"},"object":{"id":"ba62c756-407f-59e3-b9c0-95b4f80ba7c3","slug":"hpv-persistence","display_name":"Persistence of HPV positivity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"7a926a97-b287-5f42-b163-3267b258a30d","stable_key":"182336c6-ed36-5ec6-8a09-25c31096262e:dim-hpv-null-event","event_type":"observed_intervention","label":"This trial did not demonstrate improved HPV clearance.","description":"Among baseline HPV-positive women, 69% on DIM versus 61% on placebo remained positive at six months, RR 1.1 with 95% CI 0.9-1.4.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6009bdd4-f1b5-5867-b5c3-cdf7c9645cd0","slug":"dim","display_name":"3,3'-Diindolylmethane / DIM","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ba62c756-407f-59e3-b9c0-95b4f80ba7c3","slug":"hpv-persistence","display_name":"Persistence of HPV positivity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/dim-research/22075942.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617\", \"start_char\": 0, \"end_char\": 1631, \"text_sha256\": \"a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Double-blind randomized placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral DIM 150 mg/day for six months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"No demonstrated HPV/cytology benefit; CIN2+ estimates were imprecise. Not evidence that a supplement replaces screening or lesion treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"dim","display_name":"3,3'-Diindolylmethane / DIM","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"551 women available for analysis","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"This trial did not demonstrate improved HPV clearance.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[dim-p22075942] Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/22075942/ DOI: 10.1038/bjc.2011.496","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Low-grade cervical abnormalities and HPV","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8b882793-89fd-5a18-a362-f01530f0d6db","evidence_kind":"source_excerpt","locator":"Lines 1182-1193","start_line":1182,"end_line":1193,"excerpt":"### dim-hpv-null\nAmong baseline HPV-positive women, 69% on DIM versus 61% on placebo remained positive at six months, RR 1.1 with 95% CI 0.9-1.4.\nCondition category: normal\nnutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: This trial did not demonstrate improved HPV clearance.\norganism: 551 women available for analysis\ntissue_or_cell_type: Low-grade cervical abnormalities and HPV\nexperimental_model: Double-blind randomized placebo-controlled trial\nlimitations: No demonstrated HPV/cytology benefit; CIN2+ estimates were imprecise. Not evidence that a supplement replaces screening or lesion treatment.\nexposure: Oral DIM 150 mg/day for six months\nevidence_span: {\"source_cache\": \"artifacts/dim-research/22075942.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617\", \"start_char\": 0, \"end_char\": 1631, \"text_sha256\": \"a48e14708d6ab188e676830826bab1afebc6d3eecf8c80e533963f3ab67a7617\"}\n[dim-p22075942] Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/22075942/ DOI: 10.1038/bjc.2011.496","model_system":"Double-blind randomized placebo-controlled trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [dim-p22075942] Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. (2012). https://pubmed.ncbi.nlm.nih.gov/22075942/ DOI: 10.1038/bjc.2011.496","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b6d70682-97f9-5893-a03c-f9f88836033c","stable_key":"import-182336c6-ed36-5ec6-8a09-25c31096262e","title":"Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"31e14060de904976d2f5d439f2bc9c8a99a72d34626c562c78429025e050d404","revision_id":"611094c1-a9cf-5b9b-b255-ac70b571696a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}